Building a $14B Lab Business: David King on CEO Development, Decisions & Culture at Scale

Most people know LabCorp for routine blood work. But under CEO Dave King, the company expanded far beyond basic diagnostics, scaling from about $4B to $14B in revenue while navigating relentless pricing pressure, major acquisitions, and a rapidly changing healthcare landscape. In this conversation, Dave breaks down what it really takes to scale through M&A, why some deals worked and others missed expectations, and how to lead when decisions draw criticism. He also talks about Theranos, why he stayed quiet publicly, and how the science ultimately caught up. Finally, he shares how LabCorp built a unified, patient first culture across roles ranging from PhDs to couriers and phlebotomists, and why the team’s Covid response became one of his proudest moments.What you’ll hear in this episode:-The economics of the lab business and why volume matters-How Dave went from prosecutor and partner to LabCorp general counsel and then CEO-Building real compliance culture after a corporate integrity agreement-The biggest shift when you become CEO and why it takes time to learn the job-The “lazy with the numbers” moment and how it reshaped his leadership-LabCorp’s M&A strategy, including Genzyme Genetics and the Covance deal-Theranos behind the scenes and why LabCorp avoided taking the bait publicly-Navigating PAMA reimbursement cuts in a high fixed cost model-Succession, stepping away gracefully, and not becoming the “court of appeals”-How to build culture across a massive, diverse workforce-Why LabCorp’s Covid response is the moment he’s most proud ofTimestamps:00:00:00 LabCorp’s transformation and Dave King intro00:01:10 The scale story: CEO tenure, growth, and deal reality00:02:06 Early life: DC, Illinois, Berkeley00:03:10 Princeton, public affairs, Near Eastern studies00:03:32 Teaching high school and why he chose law00:04:40 Traditional legal career: clerk, prosecutor, big firm00:05:53 Meeting LabCorp through investigations00:06:31 Why he moved in house and what changed personally00:08:15 Compliance culture shift and staffing legal and compliance00:09:23 Becoming CEO later in life and why that helped00:11:31 The real CEO job versus ops leadership00:13:09 “You’re lazy with the numbers” and the habit that fixed it00:15:54 Strategy pivot: pricing pressure and broadening the revenue base00:18:17 Genzyme Genetics and building leadership in genetics00:20:23 Integration philosophy: one LabCorp culture00:22:42 Deals you do not do and what he regrets not bolstering00:24:52 Theranos: investor distraction, science reality, and why he stayed quiet00:30:50 The Covance deal: why it mattered and the precision medicine thesis00:33:10 Why Covance under delivered and what he learned00:35:13 Leadership means decisions plus criticism00:36:03 PAMA cuts: what happens in high fixed cost economics00:39:06 Retirement planning and timing00:40:35 Succession and stepping away gracefully00:43:29 Not the court of appeals: how to support the new CEO00:44:35 Culture across roles: scientists, couriers, phlebotomists00:48:09 Senior team stability and deliberate hiring00:49:47 Proud moments: the Covid response and the team’s intensity00:52:19 Closing thoughts